Kathleen Cox

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

Glucose Homeostasis, Bace1 Inhibitor Verubecestat, Enzyme 1 +20

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection<i>in vitro</i>and<i>in vivo</i>

Julie Strizki, Serena Xu, Nicole Wagner et al. · Proceedings of the National Academy of Sciences · 2001 · 300 citations · Full text

Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1

Julie Strizki, Cécile Tremblay, Serena Xu et al. · Antimicrobial Agents and Chemotherapy · 2005 · 214 citations · Full text

Antiviral Compound, Neurovirology, Medicine +15

Role of the site of protonation in the low-energy decompositions of gas-phase peptide ions

Kathleen Cox, Simon J. Gaskell, Michael Morris et al. · Journal of the American Society for Mass Spectrometry · 1996 · 177 citations

Peptide Engineering, Peptide Science, Charge Heterogeneity +21

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 161 citations · Full text

Neurochemical Biomarkers, Peptide Science, Enzyme 1 +19